Gossamer Bio Inc Revenue Growth Rates (GOSS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Gossamer Bio Inc   (NASDAQ: GOSS)
 

GOSS's Revenue Growth by Quarter and Year

Gossamer Bio Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GOSS/growth
https://api.csimarket.com/api/v1/companies/GOSS/fundamentals
https://api.csimarket.com/api/v1/companies/GOSS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
GOSS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 38.43
2nd Quarter June 9.24
1st Quarter March 16.96
FY 64.63





GOSS Revenue third quarter 2026 Y/Y Growth Comment
Gossamer Bio Inc achieved in the third quarter 2026, above Company average Revenue surge of 189.17% year on year, to $ 38.43 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 174 other companies have achieved higher Revenue growth. While Gossamer Bio Inc ' s Revenue doubling of 189.17% ranks overall at the positon no. 3669 in the third quarter 2026.


GOSS Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 189.17 %
2nd Quarter June -19.58 %
1st Quarter March 71.49 %
FY   -

Financial Statements
Gossamer Bio Inc 's third quarter 2026 Revenue $ 38.43 millions GOSS's Income Statement
Gossamer Bio Inc 's third quarter 2025 Revenue $ 13.29 millions Quarterly GOSS's Income Statement


GOSS Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 315.92 %
2nd Quarter June -45.52 %
1st Quarter March 22.9 %
FY (Year on Year)   -


Back to GOSS Growth rate Comparisons >> Back to GOSS Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #175
Healthcare Sector #519
Overall #3669

Revenue Y/Y Growth Statistics
High Average Low
32.43 % -11.5 % -55.42 %
(Jun 30 2026)   (Mar 31 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #175
Healthcare Sector #519
Overall #3669
Revenue Y/Y Growth Statistics
High Average Low
32.43 % -11.5 % -55.42 %
(Jun 30 2026)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Gossamer Bio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
22.87 % -9.09 % -90.11 %
(Mar 31 2026)  


GOSS's III. Quarter Q/Q Revenue Comment
Gossamer Bio Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 315.92%, to $ 38.43 millions, from $9.24 millions in the second quarter.
GOSS is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 177 other companies have achieved higher Revenue quarter on quarter growth. While Gossamer Bio Inc 's Revenue growth quarter on quarter, overall rank is 3643.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #178
Healthcare Sector #520
Overall #3643
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #178
Healthcare Sector #520
Overall #3643
Revenue Q/Q Growth Statistics
High Average Low
22.87 % -9.09 % -90.11 %
(Mar 31 2026)  


GOSS's III. Quarter Q/Q Revenue Comment
Gossamer Bio Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 315.92%, to $ 38.43 millions, from $9.24 millions in the second quarter.
GOSS is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 177 other companies have achieved higher Revenue quarter on quarter growth. While Gossamer Bio Inc 's Revenue growth quarter on quarter, overall rank is 3643.


Gossamer Bio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 78.42
Y / Y Revenue Growth (TTM) 78.03 %
Year on Year Revenue Growth Overall Ranking # 3634
Seqeuential Revenue Change (TTM) 47.17 %
Seq. Revenue Growth (TTM) Overall Ranking # 3669


Cumulative Revenue growth Comment
Gossamer Bio Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 78.03% year on year, to $ 78 millions if the fiscal year would have ended in Sep 30 2026.
Gossamer Bio Inc 's trailing twelve months Revenue growth was higher than company's average -11.5% and higher than 32.43% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 47.17 % from $53.29 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -11.5%.

In the Healthcare sector 505 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3256 to 3634.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 175
Healthcare Sector # 506
Overall # 3634

Revenue TTM Y/Y Growth Statistics
High Average Low
32.43 %
 -11.5 %
-55.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 175
Sector # 519
S&P 500 # 3669
Cumulative Revenue growth Comment
Gossamer Bio Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 78.03% year on year, to $ 78 millions if the fiscal year would have ended in Sep 30 2026.
Gossamer Bio Inc 's trailing twelve months Revenue growth was higher than company's average -11.5% and higher than 32.43% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 47.17 % from $53.29 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -11.5%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 47.17 % increase from $53.29 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 505 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3256 to 3634.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 175
Healthcare Sector # 506
Overall # 3634

Revenue TTM Y/Y Growth Statistics
High Average Low
32.43 %
-11.5 %
-55.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 175
Sector # 519
S&P 500 # 3669




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GOSS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Agios Pharmaceuticals Inc 330.01%$ 330.008 millions
Insmed Inc330.00%$ 330.000 millions
Monte Rosa Therapeutics Inc 325.80%$ 325.799 millions
Liquidia Corporation314.60%$ 314.596 millions
Stablecoin Development Corporation310.75%$ 310.749 millions
Renovorx Inc 300.75%$ 300.752 millions
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions
Camp4 Therapeutics Corporation138.87%$ 138.868 millions
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions


About Gossamer Bio Inc Revenue Growth Rates (GOSS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Gossamer Bio Inc (CIK 1728117).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001728117-26-000114
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Gossamer Bio Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.